Wet age-related macular degeneration Trials in Reno, United States
Conditions / Wet age-related macular degeneration / Reno, United States
Research into Wet age-related macular degeneration spans multiple therapeutic approaches and trial phases.
10 total trials for this combination
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT03748784 | ADVM-022 Intravitreal Gene Therapy for Wet AMD | COMPLETED | PHASE1 |
| NCT04704921 | Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD | ACTIVE_NOT_RECRUITING | — |
| NCT04832724 | RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD) | COMPLETED | PHASE2 |
| NCT05381948 | Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) | COMPLETED | PHASE2 |
| NCT03066258 | Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial | COMPLETED | PHASE1/PHASE2 |
| NCT05407636 | Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD | RECRUITING | PHASE3 |
| NCT04645212 | Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT] | ACTIVE_NOT_RECRUITING | — |
| NCT04964089 | A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) | COMPLETED | PHASE3 |
| NCT03790852 | Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO | TERMINATED | PHASE1 |
| NCT06668064 | A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56 | ACTIVE_NOT_RECRUITING | PHASE3 |